Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology
Noemí Álvarez(Hospital Universitario 12 De Octubre), Rosa Ayala(Hospital Universitario 12 De Octubre), Inmaculada Rapado(Wellcome Sanger Institute), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), María‐Teresa Cedena(Hospital Universitario 12 De Octubre), María Poza, Ricardo Sánchez(Research Institute Hospital 12 de Octubre), Marta Montero, Gonzalo Carreño‐Tarragona, Alba Rodríguez-García(Research Institute Hospital 12 de Octubre), M. Gutiérrez(Research Institute Hospital 12 de Octubre), María Luz Morales(Research Institute Hospital 12 de Octubre)
Cited by 2
Related Papers
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523